536 results on '"Wu, Runhui"'
Search Results
52. Oral health status and oral habits of children and adolescents with hemophilia: a report from the children’s hemophilia comprehensive care center of China
53. Treatment‐related outcome from patient report outcome (PRO) of children with severe and moderate hemophilia A in China: An analysis report of registration data from patient organization “hemophilia home care center”
54. Application of peripherally inserted central catheter in immune tolerance induction treatment of children with hemophilia A and accompanying inhibitors in China
55. Transient increase in platelet counts associated with COVID‐19 infection during TPO‐RA as the second‐line treatment in children with ITP
56. An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A
57. Mycoplasma pneumoniae pneumonia associated thrombosis at Beijing Children’s hospital
58. Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real‐world study in China
59. Sustained response off treatment in eltrombopag for children with persistent/chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China
60. Transient increase of platelet associated with COVID-19 infection during TRAs as the second-line treatment in children ITP：a single center report on the prevalence of BV7 mutant in December 2022 from Beijing, China
61. The efficacy of sequential MMF-rescue-regimen to eradicate inhibitors for refractory severe hemophilia A inhibitor children in China
62. Early immune tolerance induction is a unique predictor of favorable outcomes in hemophilia A children with intron 22 inversion and high-responding inhibitors
63. The efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China
64. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children
65. Cost‐effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate–severe to severe hemophilia B in China
66. Case report: Effectiveness of sirolimus in treating partial DiGeorge Syndrome with Autoimmune Lymphoproliferative Syndrome (ALPS)-like features
67. Machine Learning Models Developed and Internal Validated for Predicting Chronicity in Chinese Children Immune Thrombocytopenia
68. Piecewise Linear Recursive Convolution Method Applied in One-dimensional Unmagnetized Plasma
69. Application of Graphic Electromagnetic Computing in Electrically Large Scale Composite Target Scattering
70. Near-field Measurement Method for Electromagnetic Scattering of Electrically Large-scale Plasma
71. Protocol and Primary Analysis of Lome: A Randomized Trial of Low- Versus Intermediate-Dose Immune Tolerance Induction with Recombinant Factor VIII (Omfiloctocog alfa, SCT800) in China
72. Shorter Time Interval from Inhibitor Detection to Starting Low-Dose Immune Tolerance Induction Therapy Is Associated with Better Inhibitor Eradication Outcomes in Severe Hemophilia a Children with High-Titer Inhibitors in China
73. Single-Cell Sequencing of Immune Cells from Hemophilia a Patients with Inhibitors and Acquired Hemophilia a Patients
74. Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study
75. Anti‐glycoprotein autoantibodies are related to bleeding severity in children with newly diagnosed ITP and very low platelet counts
76. F9 mutations causing deletion beyond serine protease domain confer higher risk for inhibitor development in hemophilia B
77. Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
78. Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
79. Anaplastic lymphoma kinase positive histiocytosis presenting as hemocytopenia in an infant
80. “A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates”: Comment from Huang et al.
81. Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
82. Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China
83. F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B
84. Risk factors for inhibitors in hemophilia A based on RNA‐seq and DNA methylation
85. Case report: Effectiveness of sirolimus in a de novo FAS mutation leading to autoimmune lymphoproliferative syndrome-FAS and elevated DNT/Treg ratio
86. Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A
87. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A
88. Platelet-specific antibodies are unrelated to the bleeding severities in children with newly diagnosed ITP and a severe decline of platelets
89. Efficacy of hematopoietic stem cell transplantation in the treatment of children with non‐severe aplastic anemia
90. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B – the impact of prophylactic treatment
91. Single Nucleotide Polymorphisms of the HIF1A Gene are Associated With Sensitivity of Glucocorticoid Treatment in Pediatric ITP Patients.
92. Single Nucleotide Polymorphisms of the HIF1A Gene are Associated With Sensitivity of Glucocorticoid Treatment in Pediatric ITP Patients
93. Eradication of FIX inhibitor in haemophilia B children using low‐dose immune tolerance induction with rituximab‐based immunosuppressive agent(s) in China
94. Altered brain activity and functional networks in school‐age boys with severe haemophilia A: A resting‐state functional magnetic resonance imaging study
95. Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia
96. Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A
97. Efficient adaptation of high‐quality international guidelines for Chinese children with primary immune thrombocytopenia
98. Summary and Analysis of 13 RAS-Associated Autoimmune Leukoproliferative Disease Clinical Features
99. Cyclosporine Monotherapy in Pediatric Patients With Non-severe Aplastic Anemia: A Retrospective Analysis
100. Effect of Wuzhi capsules on cyclosporine A concentration in children with aplastic anemia immunotherapy: a single-center observational study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.